Navigation Links
New study reports on the high cost of cardiac surgery healthcare associated infections
Date:11/19/2013

After cardiac surgery, healthcare-associated infections (HAIs) are common complications associated with increased morbidity, mortality, and use of resources.

Study findings reported at the American Heart Association's Scientific Sessions 2013 by investigators from the Cardiothoracic Surgical Trials Network (CTSN), whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, revealed the substantial economic impact of HAIs following cardiac surgery and the importance of preventing these infections leading to re-hospitalizations.

In the new analysis, researchers examined data about the incremental costs associated with major HAIs within 65 days of cardiac surgery. Clinical data from 4,320 patients at nine academic medical centers was merged with related financial data routinely collected by the University Health Consortium in the United States. The most common cardiac surgery procedures undergone by these patients included valve surgery, coronary artery bypass graft (CABG), and CABG/valve surgery.

The data show during hospitalization, 2.7 percent of patients experienced major infections, such as pneumonia, sepsis, C. Difficile, and surgical site infections.

The average cost due to treating major HAI infection was calculated as about $40,000, with increased costs from Intensive Care Unit stays being an important contributing factor. Also, patients with major HAIs were nearly twice as likely to be readmitted as those with non-HAIs. In the patient population studied, there were 74 readmissions, with 8.7 percent due to HAIs.

"Our analysis found readmissions due to HAIs, after cardiac surgery cost on average nearly three times as much as non-HAI related readmissions," says Giampaolo Greco, PhD, Assistant Professor of Health Evidence and Policy at Icahn School of Medicine at Mount Sinai.

"We need to take action to avert preventable readmissions due to HAI infection rates after cardiac surgery, first for the patient's health and also to curb rising healthcare costs," says Dr. Greco.

This study was funded by the National Institutes of Health and Institute for Health Technology Studies (InHealth), a non-profit foundation.

As principal investigator for CTSN's Data and Clinical Coordinating Center based at Mount Sinai, Annetine C. Gelijns, PhD, Professor and Chair of the Department of Health Evidence and Policy at Icahn School of Medicine at Mount Sinai, previously received financial compensation as a consultant for InHealth's Research Council, which has supported some of the study-related analyses.

This study was presented at the AHA Scientific Sessions 2013 in Abstract Poster Session (18267): The Economic Impact of Healthcare Associated Infections in Cardiac Surgery.


'/>"/>

Contact: Lauren Woods
Lauren.woods@mountsinai.org
646-634-0869
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert  

Related medicine news :

1. New Study May Impact Practice Guidelines for Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation
2. Study may impact guidelines for mitral valve surgery for severe ischemic mitral regurgitation
3. Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows
4. Chicago man breathes again thanks to Northwestern Medicine study
5. Study finds youth prefer and benefit more from rapid point-of-care HIV testing
6. Study: Ureteral injury during robot-assisted prostate surgery
7. Study: Odds of rehospitalization of cognitively impaired varies by discharge destination
8. A CNIO study recreates the history of life through the genome
9. Dr. Joe Dentistry Promotes Dental Exams as New Study Links Heart Disease to Oral Health
10. Study questions hypothermia treatment for cardiac arrest
11. Mayo Clinic-led study: 2 drugs do not improve kidney function in acute heart failure patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New study reports on the high cost of cardiac surgery healthcare associated infections
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: